The impact of valproic acid treatment on weight gain in pediatric patients with epilepsy

Domenica Immacolata Battaglia, Pietro Ferrara, Valeria Blasi, Antonio Gatto, Federica DI Ruscio

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

Abstract

Background: Valproic acid (VPA) is an antiepileptic drug, used for focal and generalized seizure. VPA treatment resulted in significant weight gain but there are no systematic data about the prevalence of this side effect. The aim of the study is to evaluate the weight gain of a paediatric population with epilepsy. Methods: We enrolled 38 patients, 17 female and 21 male with a mean age of 8.2±4.4 years. We evaluated data about height, weight and BMI at beginning of treatment and at 24, 36 and 48 months of follow-up. Results: There is a statistical significant difference between the percentile value of weight and BMI at baseline and at 36 and 48 months of follow-up (P value <0.01) but there isn't statistical significant difference between the percentile value of height (P value 0.22 and 0.18). Conclusions: We believe that a nutritional support should be guaranteed to the pediatric patients with epilepsy that begin the VPA therapy.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaMinerva Pediatrica
DOI
Stato di pubblicazionePubblicato - 2017

Keywords

  • antiepilectic drugs
  • children
  • epilepsy

Fingerprint Entra nei temi di ricerca di 'The impact of valproic acid treatment on weight gain in pediatric patients with epilepsy'. Insieme formano una fingerprint unica.

Cita questo